Design of Selective PARP‑1 Inhibitors and Antitumor Studies

Designing selective PARP-1 inhibitors has become a new
strategy
for anticancer drug development. By sequence comparison of PARP-1
and PARP-2, we identified a possible selective site (S site) consisting
of several different amino acid residues of α-5 helix and D-loop.
Targeting this S site, 140 compounds were designed, synthesized, and
characterized for their anticancer activities and mechanisms. Compound I16 showed the highest PARP-1 enzyme inhibitory activity (IC50 = 12.38 ± 1.33 nM) and optimal selectivity index over
PARP-2 (SI = 155.74). Oral administration of I16 (25
mg/kg) showed high inhibition rates of Hela and SK-OV-3 tumor cell
xenograft models, both of which were higher than those of the oral
positive drug Olaparib (50 mg/kg). In addition, I16 has
an excellent safety profile, without significant toxicity at high
oral doses. These findings provide a novel design strategy and chemotype
for the development of safe, efficient, and highly selective PARP-1
inhibitors.